Glenn J. Hanna, MD, discusses the preliminary antitumor activity and manageable safety profile of micvotabart pelidotin in head and neck squamous cell carcinoma.
Glenn J. Hanna, MD
Advertisement
Glenn J. Hanna, MD, is the director of the Center for Cancer Therapeutic Innovation (Early Drug Development Program) and director of the Center for Salivary and Rare Head and Neck Cancers at Dana-Farber Cancer Institute; as well as an associate professor of medicine at Harvard Medical School
Articles by Glenn J. Hanna, MD
Glenn J. Hanna, MD, discusses the efficacy of elraglusib plus chemotherapy with or without immunotherapy in patients with advanced salivary gland cancer.
Glenn J. Hanna, MD, discusses the significance of the FDA approval of toripalimab for patients with recurrent or metastatic nasopharyngeal carcinoma.
Advertisement
Latest Updated Articles
Dr Hanna on Elraglusib Plus Chemotherapy and Immunotherapy in Advanced Salivary Gland CancerPublished: April 29th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5